FRI0299 THE PREVALENCE OF NON-VASCULAR PULMONARY MANIFESTATIONS IN PATIENTS WITH TAKAYASU’ ARTERITIS: A RETROSPECTIVE MULTI-CENTERED COHORT STUDY
Authors: Ayten Yazici, Ayse Cefle, Sema Kaymaz Tahra, Nilüfer Alpay Kanıtez, Mete Kara, Önay Gerçik, Handan Yarkan Tugsal, Fatos Onen, Servet Akar, Kenan Aksu, Gökhan Keser, Fatma Alibaz-Oner, Haner Direskeneli
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Takayasu' arteritis (TAK) is a rare vasculitis characterized by inflammation and obliteration of intermediate to large-size arteries. Even though more than 50% of patients with TAK have pulmonary artery involvement, non-vascular involvement and symptoms are uncommon. <h3>Objectives</h3> We aimed to investigate the frequency of non-vascular pulmonary involvement in TAK. <h3>Methods</h3> We assembled a retrospective cohort of patients with TAK from six different centers in Turkey. The demographics, clinical characteristics, treatment and outcomes of patients were abstracted from medical records, and the computed tomography findings were evaluated for pulmonary manifestations. <h3>Results</h3> As of January 2019, 197 TAK patients were recruited (mean age: 42.7±13.9 years [min-max: 17-75]) to the cohort, and 88.3% of them were female. Twenty-four patients had cough and/or dyspnea and four had hemoptysis as pulmonary symptoms. In CT assessment, parenchymal infiltrations were present in four (2%), pleural effusion in five (2.5%), nodule/cavity in one (0.5%), and pulmonary hemorrhage in one patient (0.5%). The patient who had pulmonary hemorrhage had also pleural effusion at the same time. In the whole cohort, 11.2% of patients (n=22) had pulmonary hypertension (PAH), three of them had cough and/or dyspnea and four of them had hemoptysis as a pulmonary symptom. Among patients with PAH, any pulmonary involvement in CT was more frequent compared to the rest of the patients (22.7% vs 5.1%, p&lt;0.0001) (Table 1). <h3>Conclusion</h3> In this first assessment of Turkish TAK cohort, we observed non-vascular pulmonary involvement in about 5% of our patients and half of them were pleural effusions. The second most common manifestation was parenchymal infiltration with a frequency of 2%. Although rare, non-vascular pulmonary manifestations should also be investigated in TAK patients, especially in patients with pulmonary hypertension. <h3>References</h3> [1] Nakajima N. Takayasu Arteritis: Consideration of pulmonary involvement. Ann Vasc Dis2008;1(1):7-10. [2] Elsasser S, Soler M, Bollinger CT, et al. Takayasu disease with predominant pulmonary involvement. Respiration2000;67(2):213-5. <h3>Disclosure of Interests</h3> Ayten Yazici: None declared, Ayse Cefle: None declared, Sema Kaymaz Tahra: None declared, Nilüfer Alpay Kanıtez: None declared, Mete Kara: None declared, Önay Gerçik: None declared, Handan Yarkan Tugsal: None declared, Fatos Onen: None declared, Servet Akar Grant/research support from: MSD, Abbvie, Roche, UCB, Novartis, Pfizer, Amgen, Consultant for: MSD, Abbvie, Roche, UCB, Novartis, Pfizer, Amgen, Speakers bureau: Pfizer, Kenan Aksu: None declared, Gökhan Keser: None declared, Fatma Alibaz-Oner: None declared, Haner Direskeneli: None declared